Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

S and AML Patients

CHICAGO, Ill. June 2, 2007 - Pharmion Corporation (NASDAQ:PHRM) and MethylGene Inc. (TSX:MYG) today announced preliminary Phase II and Phase I/II data for their lead oncology product candidate, MGCD0103, a novel, isotype-selective histone deacetylase (HDAC) inhibitor which showed significant anti-tumor activity in patients with Hodgkin's lymphoma, Myelodysplastic Syndromes and acute myelogenous leukemia. The data were presented Saturday at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Hodgkin's Lymphoma (Trial 010)

Data presented show an objective complete and partial response rate of 40 percent and a disease control rate of 45 percent in a population of patients that had relapsed disease or were refractory (unresponsive) to all previous treatments, including, in many cases, bone marrow transplantation. Overall, 75 percent of patients experienced a reduction in tumor size, with 60 percent experiencing a tumor reduction of greater than 30 percent.

"It is striking that single-agent therapy with MGCD0103 achieved such impressive objective clinical responses in this population," said Anas Younes, M.D., principal investigator and Professor of Medicine and Director, Clinical Investigation and Translational Research in the Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center. "No approved therapies exist for patients suffering from Hodgkin's lymphoma that has progressed following transplantation. With a novel mechanism of action and an oral route of administration, MGCD0103 would be a welcome and desirable addition to the Hodgkin's lymphoma armamentarium."

The data were presented as part of a clinical symposium titled, "Breaking the Silence of the Genome: HDAC Inhibitors," which focused on the progress and potential of this emerging therapeutic category. The HDACs are enzymes that mediate histone deacetylation, an epigenetic form of gene regulation that may silence tumor suppres
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... SAN DIEGO, Aug. 4, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... for the quarter ended June 30, 2011. (Logo: ... for the second quarter of 2011 of $24.2 million, or ... as compared to a net loss for the second ...
... Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will release financial results for the second ... Monday, August 15, 2011 before the start of trading ...
Cached Medicine Technology:Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 2Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 3Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 4Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 5Dehaier Medical to Report Second Quarter 2011 Financial Results on August 15 2
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... Jenifer Goodwin HealthDay Reporter , TUESDAY, Sept. 6 ... to fold laundry, mow the lawn or stand in line, ... bay. New research finds that seniors who expended the ... ones and simply going about their business were less likely ...
... , TUESDAY, Sept. 6 (HealthDay News) -- There,s no ... heart disease, says a study that challenges a long-held ... women spikes after menopause. Aging alone, not the ... deaths among older women, according to the Johns Hopkins ...
... Pediatric obesity ends up costing $3 billion annually in ... be saved by streamlining medical coverage to address health ... to treat conditions they develop as they get older, ... morbidly obese children, access to multidisciplinary services can lead ...
... Reporter , MONDAY, Sept. 5 (HealthDay News) -- An ... into the U.S. blood supply and doctors need to ... Babesiosis is a parasitic infection that is transmitted through ... range from mild flu-like symptoms to severe difficulty with ...
... at Columbia University,s Mailman School of Public Health heightens ... a group of ubiquitous chemicals known as phthalates. Phthalates ... disrupt the endocrine system, and are widely used in ... materials, to shampoos. Recent studies of school-age children ...
... Psychogenic non-epileptic seizures may go undiagnosed for much longer in ... in the September 6, 2011, print issue of Neurology ... This type of seizure is different from seizures related to ... "People with psychogenic seizures are often diagnosed with epilepsy and ...
Cached Medicine News:Health News:Routine Chores Might Help Keep Dementia at Bay 2Health News:Routine Chores Might Help Keep Dementia at Bay 3Health News:Routine Chores Might Help Keep Dementia at Bay 4Health News:Aging, Not Menopause, Raises Women's Heart Risks, Study Finds 2Health News:Study finds payment for pediatric obesity services now can save money later 2Health News:Tick-borne Illness May Lurk in Blood Supply 2Health News:Tick-borne Illness May Lurk in Blood Supply 3Health News:Prenatal exposure to phthalates linked to decreased mental and motor development 2Health News:Non-epileptic seizures may be misdiagnosed longer in veterans 2
... In the way it implements the ... 510 Meta system is unmatched. It allows ... compromising resolution and efficiency. Unprecedented flexibility for ... functions that guarantee fast and efficient structural ...
... first inverted microscope to take full advantage ... design enables optical input/output of light and ... and detector equipment. Extendable "Stratum Structure" configuration ... source and other attachments within the infinity ...
... with direct digital output. Three-chip color camera ... wide array of high-quality color video cameras ... flexibility you need for an efficient viewing ... real-time image of your specimen that can ...
... The PM30 is a premium photomicrography ... quality photomicrographs of even the most difficult ... the new PM30 system provide solution to ... addition to their automatic exposure control, the ...
Medicine Products: